Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026

Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Vaccine Contract Manufacturing Market Report

The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026.

The global vaccine contract manufacturing market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrophe. Vaccine CMOs have gained significant attention as the virus starts spreading far and wide. A new era of vaccine and biological drug development has prevailed since the advent of the COVID-19 virus. The global pandemic has fueled vaccine innovations with the rapid acceleration of RNA-based COVID vaccines. Contract manufacturing companies are working to increase the availability of COVID-19 vaccines across the globe.

The vaccine manufacturing landscape has changed dramatically over few decades. Almost three-fourths of pharma and biotech companies have entered into mergers and agreements with contract manufacturers to develop COVID-19 vaccines. Outsourcing has gained high significance as it offers significant advantages such as end-to-end manufacturing solutions and expertise in vaccine manufacturing. A high level of capital expenditure combined with complexity for manufacturing has limited the entry of new players. With maturing pipelines of vaccine products, biotech companies face decisions to partner with existing manufacturers or contract manufacturers or develop in-house manufacturing capabilities.

The following factors are likely to contribute to the growth of the vaccine contract manufacturing market during the forecast period:
Global COVID-19 Vaccination Programs
Manufacturers’ focus on Scale-up Vaccine Production
Growing Agreements between Vaccine Developers and Contract Manufacturers
Vaccine pipeline boosting demand for Contract Manufacturing

The study considers the global vaccine contract manufacturing market’s present scenario and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.


The global commercial vaccine contract manufacturing market accounted for over 64% in 2020. There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide. North America expects to contribute maximum revenue to the commercial vaccine market due to the increased focus to prevent deaths caused by vaccine-preventable diseases. The emergence of the RNA platform has accelerated the vaccine development process.

The clinical vaccine contract manufacturing market is expected to witness an incremental growth of over USD 492 million during the forecast period. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 and the Ebola and Lassa fever epidemics in Western and Southern Africa demonstrate an urgent need for vaccines and therapeutics against emerging and re-emerging infectious diseases. Several serums are in the pipeline for wide-ranging contagious diseases and COVID-19, which are likely to boost the market growth. The preclinical segment accounted for a share of 13% of the global vaccine contract manufacturing market in 2020. Growing populations, healthcare awareness, demand for newer vaccination products, increasing global vaccination coverage are also some of the factors for the increased need for immunizations globally.

Sub-unit vaccines accounted for a major share of approx. 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period. Growing infectious diseases leading to endemic/pandemics, majorly due to decreasing immunization coverage in many regions, have made national and international bodies implement vaccination programs strictly, allowing more people to get vaccinated. This is likely to increase the demand for vaccine production and benefit CMOs’ expertise in the manufacturing services. Contract manufacturing service agreements are high for recombinant vector COVID-19 vaccines.

The fill/finish services market expects to grow at a CAGR of approx. 13% during 2020-2026. Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process. Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales. Moreover, biopharmaceutical companies outsource fill-and-finish needs to gain access to specialized technology. CMOs are extremely helpful in meeting balanced production volumes and commercial validation of manufactured products. Hence, the growth in biopharmaceuticals is likely to fuel the demand for fill-and-finish contract services.

The analytical and QC studies services market is expected to observe an incremental growth of over USD 322 million by 2026. An increase in product-pipeline manufacturing requiring both method development and method validation drives several biopharmaceutical companies to opt for analytical method development services. CMOs perform method development, method validation, manufacturing support, release testing, and stability. Hence, the demand for analytical and QC studies services expected to grow in biopharmaceutical companies.

Scale of Operation

Vaccine Type
Live Attenuated

Analytical & QC Studies
Cell/Virus Banking


North America has the most widespread contract manufacturing organizations, with nearly 40 CMOs present at several US locations. The US accounted for over 90% of the North American vaccine contract manufacturing market share. The increasing trend of outsourcing is benefitting contract manufacturers in the region. Regulations related to vaccine manufacturing, especially in the US and Canada, are boosting the market growth. The prevalence of infectious diseases and the increasing number of deaths due to vaccine-preventable diseases has increased the need for manufacturing.
Europe accounted for the second-highest share of 26% in the vaccine contract manufacturing market in 2020. The increasing elderly population, prevalence of bacterial and viral infections, increasing demand of new vaccinations, and expanding biopharma and biotech industry are major factors contributing to the growth of contract manufacturing in the Europe region. APAC witnesses growing market demand mainly due to a large and growing population which increases the access to vaccines. In APAC, various opportunities associated with the growing vaccine pipeline, rise in outsourcing of vaccine manufacturing services, implementation of novel and innovative technologies are expected to have a significant influence on the future of the vaccine contract manufacturing market.

North America
South Korea
Latin America
Middle East & Africa
Saudi Arabia
South Africa


Ajinomoto BioPharma, Albany Molecular Research Institute, Catalent, Cytovance Biologics, Emergent Biosolutions, Fujifilm Diosynth Biotechnologies, and GlaxoSmithKline are a few vendors accounting for the global vaccine contract manufacturing market share. Established players are entering into strategic alliances and co-marketing agreements to elevate the market competitiveness and penetration. They also make long-term relationships with distributors and suppliers for scale-up production and expand geographical presence in the market. North America offers a high quantity of contract manufacturing services. Europe and APAC have a few prominent players and several small and mid-sized vendors. Emerging economies, including China, India, Brazil, and Mexico, are likely to offer significant growth opportunities for vendors. Vaccine contract manufacturing companies in India are show promise as the two biopharmaceutical companies - Serum Institute of India and Bharat Biotech- have also received emergency approvals for their serums.

Prominent Vendors
Ajinomoto Bio-Pharma
Albany Molecular Research (AMRI)
Cytovance Biologics
Emergent BioSolutions
IDT Biologika
Merck KGaA
Serum Institute of India
Siegfried Holding

Other Prominent Vendors
Cobra Biologics
Baxter BioPharma Solutions
Goodwin Biotechnology
KBI Biopharma
Bavarian Nordic
Charles River Laboratories
Boehringer Ingelheim
Samsung Biologics
Meridian Life Science
Wacker Biotech B.V
Jubilant HollisterStier
Kemwell Biopharma
Northway Biotech
Midas Pharma
Pharmaceutics International Inc. (Pii)
Singota Solutions
Thermo Fisher Scientific
Kaneka Eurogentec
Richter-Helm BioLogics
Ology Bioservices
Corden Pharma
Cerbios Pharma
BSP Pharmaceuticals
JOINN Biologics
Eurofins Scientific
Esco Aster
Genovior Biotech
AGC Biologics
Amaran Biotech
Eden Biologics
Cell Culture Company
Taron Solutions
Axcellerate Pharma
WuXi Biologics
Therapure Biopharma

1. How big is the vaccine contract manufacturing market?
2. Which segment is likely to generate the largest revenue during the forecast period?
3. Which region has the largest number of vaccine manufacturers?
4. Who are the top vaccine manufacturers?
5. How has COVID-19 pandemic affected contract manufacturing companies?
6. What limitations are associated with the supply of COVID-19 vaccines for CMOs?

1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation By Scale Of Operation:
4.4.2 Market Segmentation By Vaccine Type
4.4.3 Market Segmentation By Service
4.5.1 Market Segmentation By Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Advantages Associated with Contract Manufacturing Organization (CMO)
7.1.2 CMOs Gaining More Acceptance in Biopharmaceutical Industry
7.1.3 Characteristics of An Effective CMO
8 Market Opportunities & Trends
8.1 Global Vaccination Programs For COVID-19
8.2 Manufacturers’ Focus On Scale-Up Vaccine Production
8.3 Growing Agreements Between Vaccine Developers And Contract Manufacturers
8.4 Vaccine Pipeline Boosting The Demand For Contract Manufacturing
9 Market Growth Enablers
9.1 Favorable Patient Demographics & Growing Vaccinations Of Newborns And Children
9.2 Effect Of Epidemics & Pandemics On Vaccine Development
9.3 Cost-Effective And Time-Saving Services Of Contract Manufacturers
10 Market Restraints
10.1 High Costs and Stockout Issues Of Vaccines
10.2 Lack Of Storage Infrastructure & Limitations Associated With Supply Chain
10.3 Vaccination Concerns In Low And Middle Income Countries
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Vaccine Supply Chain And Procurement During COVID-19
11.3 Five Forces Analysis
11.3.1 Threat Of New Entrants
11.3.2 Bargaining Power Of Suppliers
11.3.3 Bargaining Power Of Buyers
11.3.4 Threat Of Substitutes
11.3.5 Competitive Rivalry
12 Scale of Operations
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Commercial
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Commercial: Geography Segmentation
12.4 Clinical
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Clinical: Geography Segmentation
12.5 Preclinical
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.5.3 Preclinical: Geography Segmentation
13 Vaccine Type
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Sub-Unit Vaccines
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Sub-unit Vaccines: Geography Segmentation
13.4 Live-Attenuated Vaccines
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Live-Attenuated Vaccines: Geography Segmentation
13.5 Inactivated Vaccines
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Inactivated Vaccines: Geography Segmentation
13.6 RNA Vaccines
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.6.3 RNA Vaccines: Geography Segmentation
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast
13.7.3 Others: Geography Segmentation
14 Service
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Fill/Finish
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Fill/Finish: Geography Segmentation
14.4 Analytical & QC Studies
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Analytical & QC Studies: Geography Segmentation
14.5 Cell/Virus Banking
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.5.3 Cell/Virus Banking: Geography Segmentation
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.6.3 Others: Geography Segmentation
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 North America: Scale Of Operations
16.4 North America: Vaccine Type Segmentation
16.5 North America: Service Segmentation
16.6 Key Countries
16.6.1 US: Market Size & Forecast
16.6.2 Canada: Market Size & Forecast
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Europe: Scale Of Operations Segmentation
17.4 Europe: Vaccine Type Segmentation
17.5 Europe: Service Segmentation
17.6 Key Countries
17.6.1 Germany: Market Size & Forecast
17.6.2 UK: Market Size & Forecast
17.6.3 France: Market Size & Forecast
17.6.4 Italy: Market Size & Forecast
17.6.5 Spain: Market Size & Forecast
18.1 Market Overview
18.2 Market Size & Forecast
18.3 APAC: Scale Of Operations Segmentation
18.4 APAC: Vaccine Type Segmentation
18.5 APAC: Service Segmentation
18.6 Key Countries
18.6.1 China: Market Size & Forecast
18.6.2 India: Market Size & Forecast
18.6.3 Japan: Market Size & Forecast
18.6.4 South Korea: Market Size & Forecast
18.6.5 Australia: Market Size & Forecast
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Latin America: Scale Of Operations Segmentation
19.4 Latin America: Vaccine Type Segmentation
19.5 Latin America: Service Segmentation
19.6 Key Countries
19.6.1 Brazil: Market Size & Forecast
19.6.2 Mexico: Market Size & Forecast
19.6.3 Argentina: Market Size & Forecast
20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Middle East & Africa: Scale Of Operations Segmentation
20.4 Middle East & Africa: Vaccine Type Segmentation
20.5 Middle East & Africa: Service Segmentation
20.6 Key Countries
20.6.1 South Africa: Market Size & Forecast
20.6.2 Saudi Arabia: Market Size & Forecast
20.6.3 Turkey: Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Ajinomoto
21.2.2 Albany Molecular Research
21.2.3 Catalent
21.2.4 Cytovance Biologics
21.2.5 Emergent BioSolutions
21.2.6 FUJIFILM Diosynth Biotechnologies
21.2.7 GSK
21.2.8 IDT Biologika
21.2.9 Lonza
21.2.10 Merck KGaA
21.2.11 Pfizer
21.2.12 Recipharm
21.2.13 Serum Institute of India
21.2.14 Siegfried
22 Key Company Profiles
22.1.1 Business Overview
22.1.2 Ajinomoto in the Vaccine Contract Manufacturing Market
22.1.3 Service Offerings
22.1.4 Key Strategies
22.1.5 Key Strengths
22.1.6 Key Opportunities
22.2 ALBANY Molecular Research
22.2.1 Business Overview
22.2.2 Albany Molecular Research in the Vaccine Contract Manufacturing Market
22.2.3 Service Offerings
22.2.4 Key Strategies
22.2.5 Key Strengths
22.2.6 Key Opportunities
22.3 Catalent
22.3.1 Business Overview
22.3.2 Catalent in the Vaccine Contract Manufacturing Market
22.3.3 Service Offerings
22.3.4 Key Strategies
22.3.5 Key Strengths
22.3.6 Key Opportunities
22.4 Cytovance Biologics
22.4.1 Business Overview
22.4.2 Cytovance Biologics in the Vaccine Contract Manufacturing Market
22.4.3 Service Offerings
22.4.4 Key Strategies
22.4.5 Key Strengths
22.4.6 Key Opportunities
22.5 Emergent Biosolutions
22.5.1 Business Overview
22.5.2 Emergent BioSolutions in the Vaccine Contract Manufacturing Market
22.5.3 Service Offerings
22.5.4 Key Strategies
22.5.5 Key Strengths
22.5.6 Key Opportunities
22.6 Fujifilm
22.6.1 Business Overview
22.6.2 Fujifilm in the Vaccine Contract Manufacturing Market
22.6.3 Service Offerings
22.6.4 Key Strategies
22.6.5 Key Strengths
22.6.6 Key Opportunities
22.7 GSK
22.7.1 Business Overview
22.7.2 GSK in the Vaccine Contract Manufacturing Market
22.7.3 Service Offerings
22.7.4 Key Strategies
22.7.5 Key Strengths
22.7.6 Key Opportunities
22.8 IDT Biologika
22.8.1 Business Overview
22.8.2 IDT Biologika in the Vaccine Contract Manufacturing Market
22.8.3 Service Offerings
22.8.4 Key Strategies
22.8.5 Key Strengths
22.8.6 Key Opportunities
22.9 LONZA
22.9.1 Business Overview
22.9.2 Lonza in the Vaccine Contract Manufacturing Market
22.9.3 Service Offerings
22.9.4 Key Strategies
22.9.5 Key Strengths
22.9.6 Key Opportunities
22.10.1 Business Overview
22.10.2 Merck in the Vaccine Contract Manufacturing Market
22.10.3 Service Offerings
22.10.4 Key Strategies
22.10.5 Key Strengths
22.10.6 Key Opportunities
22.11 PFIZER
22.11.1 Business Overview
22.11.2 Pfizer in the Vaccine Contract Manufacturing Market
22.11.3 Service Offerings
22.11.4 Key Strategies
22.11.5 Key Strengths
22.11.6 Key Opportunities
22.12.1 Business Overview
22.12.2 Recipharm in the Vaccine Contract Manufacturing Market
22.12.3 Service Offerings
22.12.4 Key Strategies
22.12.5 Key Strengths
22.12.6 Key Opportunities
22.13 SERUM Institute of India
22.13.1 Business Overview
22.13.2 Serum Institute of India in the Vaccine Contract Manufacturing Market
22.13.3 Service Offerings
22.13.4 Key Strategies
22.13.5 Key Strengths
22.13.6 Key Opportunities
22.14.1 Business Overview
22.14.2 Siegfried in the Vaccine Contract Manufacturing Market
22.14.3 Service Offerings
22.14.4 Key Strategies
22.14.5 Key Strengths
22.14.6 Key Opportunities
23 Other Prominent Vendors
23.1 Cobra Biologics
23.1.1 Business Overview
23.1.2 Service Offerings
23.2 Baxter Healthcare
23.2.1 Business Overview
23.2.2 Service Offerings
23.3 Goodwin Biotechnology
23.3.1 Business Overview
23.3.2 Service Offerings
23.4 KBI Biopharma
23.4.1 Business Overview
23.4.2 Service Offerings
23.5 Sanofi
23.5.1 Business Overview
23.5.2 Service Offerings
23.6 Biomarc
23.6.1 Business Overview
23.6.2 Service Offerings
23.7 Bavarian Nordic
23.7.1 Business Overview
23.7.2 Service Offerings
23.8 Charles River Laboratories
23.8.1 Business Overview
23.8.2 Service Offerings
23.9 Boehringer Ingelheim
23.9.1 Business Overview
23.9.2 Service Offerings
23.10 Samsung Biologics
23.10.1 Business Overview
23.10.2 Service Offerings
23.11 Meridian Life Science
23.11.1 Business Overview
23.11.2 Service Offerings
23.12 Wacker Biotech B.V
23.12.1 Business Overview
23.12.2 Service Offerings
23.13 Jubilant Hollisterstier
23.13.1 Business Overview
23.13.2 Service Offerings
23.14 Abbvie
23.14.1 Business Overview
23.14.2 Service Offerings
23.15 Novasep
23.15.1 Business Overview
23.15.2 Service Offerings
23.16 Kemwell Biopharma
23.16.1 Business Overview
23.16.2 Service Offerings
23.17 Northway Biotech
23.17.1 Business Overview
23.17.2 Service Offerings
23.18 Midas Pharma
23.18.1 Business Overview
23.18.2 Service Offerings
23.19 ALCAMI
23.19.1 Business Overview
23.19.2 Service Offerings
23.20 Cambrex
23.20.1 Business Overview
23.20.2 Service Offerings
23.21 Asymchem
23.21.1 Business Overview
23.21.2 Service Offerings
23.22 Pharmaceutics International
23.22.1 Business Overview
23.22.2 Service Offerings
23.23 Sharp
23.23.1 Business Overview
23.23.2 Service Offerings
23.24 Singota Solutions
23.24.1 Business Overview
23.24.2 Service Offerings
23.25 Thermo Fisher Scientific
23.25.1 Business Overview
23.25.2 Service Offerings
23.26 Kaneka Eurogentec
23.26.1 Business Overview
23.26.2 Service Offerings
23.27 Richter-Helm Biologics
23.27.1 Business Overview
23.27.2 Service Offerings
23.28 OLOGY Bioservices
23.28.1 Business Overview
23.28.2 Service Offerings
23.29 Corden Pharma
23.29.1 Business Overview
23.29.2 Service Offerings
23.30 Cerbios Pharma
23.30.1 Business Overview
23.30.2 Service Offerings
23.31 BSP Pharmaceuticals
23.31.1 Business Overview
23.31.2 Service Offerings
23.32 Joinn Biologics
23.32.1 Business Overview
23.32.2 Service Offerings
23.33 Eurofins Scientific
23.33.1 Business Overview
23.33.2 Service Offerings
23.34 Probiogen
23.34.1 Business Overview
23.34.2 Service Offerings
23.35 ESCO Aster
23.35.1 Business Overview
23.35.2 Service Offerings
23.36 Genovior Biotech
23.36.1 Business Overview
23.36.2 Service Offerings
23.37 AGC Biologics
23.37.1 Business Overview
23.37.2 Service Offerings
23.38.1 Business Overview
23.38.2 Service Offerings
23.39 Amaran Biotech
23.39.1 Business Overview
23.39.2 Service Offerings
23.40 EDEN Biologics
23.40.1 Business Overview
23.40.2 Service Offerings
23.41 ABZENA
23.41.1 Business Overview
23.41.2 Service Offerings
23.42.1 Business Overview
23.42.2 Service Offerings
23.43 Cell Culture Company
23.43.1 Business Overview
23.43.2 Service Offerings
23.44 Taron Solutions
23.44.1 Business Overview
23.44.2 Service Offerings
23.45.1 Business Overview
23.45.2 Service Offerings
23.46 AXCELLERATE Pharma
23.46.1 Business Overview
23.46.2 Service Offerings
23.47 WUXI Biologics
23.47.1 Business Overview
23.47.2 Service Offerings
23.48 Therapure Biopharma
23.48.1 Business Overview
23.48.2 Service Offerings
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 Market By Scale Of Operation
25.1.1 North America: Scale of Operations Segmentation
25.1.2 Europe: Scale of Operations Segmentation
25.1.3 APAC: Scale of Operations Segmentation
25.1.4 Latin America: Scale of Operations Segmentation
25.1.5 Middle East & Africa: Scale of Operations Segmentation
25.2 Market By Vaccine Type
25.2.1 North America: Vaccine Type Segmentation
25.2.2 Europe: Vaccine Type Segmentation
25.2.3 APAC: Vaccine Type Segmentation
25.2.4 Latin America: Vaccine Type Segmentation
25.2.5 Middle East & Africa: Vaccine Type Segmentation
25.3 Market By Service
25.3.1 North America: Service Segmentation
25.3.2 Europe: Service Segmentation
25.3.3 APAC: Service Segmentation
25.3.4 Latin America: Service Segmentation
25.3.5 Middle East & Africa: Service Segmentation
25.4 Market By Geography
25.4.1 Commercial: Geography Segmentation
25.4.2 Clinical: Geography Segmentation
25.4.3 Preclinical: Geography Segmentation
25.4.4 Sub-Unit Vaccines: Geography Segmentation
25.4.5 Live-attenuated Vaccines: Geography Segmentation
25.4.6 Inactivated Vaccines: Geography Segmentation
25.4.7 RNA Vaccines: Geography Segmentation
25.4.8 Others: Geography Segmentation
25.4.9 Fill/Finish: Geography Segmentation
25.4.10 Analytical & QC Studies: Geography Segmentation
25.4.11 Cell/Virus Banking: Geography Segmentation
25.4.12 Others: Geography Segmentation
26 Appendix
26.1 Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings